{
    "label": "Age of patient?",
    "node_type": "fieldset",
    "children": [
        {
            "label": "For patients 18 years or older",
            "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Adjunct to a reduced calorie diet and increased physical activity for chronic weight management",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Initial body mass index (BMI) of",
                    "node_type": "checkbox",
                    "node_value": false,
                    "children": [
                        {
                            "label": "Greater than or equal to 30 kg/m^2 (obese)",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Greater than or equal to 27 kg/m^2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)",
                            "node_type": "checkbox",
                            "node_value": false
                        }
                    ]
                },
                {
                    "label": "Wegovy will not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist",
                    "node_type": "checkbox",
                    "node_value": false
                }
            ]
        },
        {
            "label": "For patients aged 12 to 17 years",
            "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Adjunct to a reduced calorie diet and increased physical activity for chronic weight management",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Initial BMI at the 95th percentile or greater, standardized for age and sex (obesity)",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Wegovy will not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist",
                    "node_type": "checkbox",
                    "node_value": false
                }
            ]
        }
    ]
}